The WHO has added the MVA-BN vaccine by Bavarian Nordic A/S to its list of prequalified vaccines against monkeypox, aiming to enhance access in high-need regions. The vaccine is effective at 76% with one dose and over 80% with two doses. Monkeypox was declared a global emergency in August 2024 amid widespread outbreaks.